{"preliminary_commentary":{"by_channel":{"bluesky_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05501704","nct_id":"NCT05501704","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05501704. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will be randomly assigned to receive Tamoxifen 1x daily for 3 weeks (21days).","label":"Window Phase Arm A: Tamoxifen","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days).","label":"Window Phase Arm B: Anastrozole","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days) and Degarelix on day 1 only.","label":"Window Phase Arm C: Anastrozole + Degarelix","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Tamoxifen 1x daily for 4 cycles (4 months); each study cycle is 28 days.","label":"Neoadjuvant Phase Arm D: Tamoxifen","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Tamoxifen 1x daily and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.","label":"Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Anastrozole 1x daily and Degarelix on day 1 of each cycle for 4 cycles (4 months); each study cycle is 28 days.","label":"Neoadjuvant Phase Arm F: Anastrozole and Degarelix","type":"EXPERIMENTAL"},{"description":"Participants will be randomly assigned to receive Anastrozole 1x daily, Degarelix on day 1 of each cycle and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.","label":"Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib","type":"EXPERIMENTAL"}],"collaborators":["Eli Lilly and Company","Translational Breast Cancer Research Consortium"],"completion_date":{"date":"2036-04-01","type":"ESTIMATED"},"conditions":["Male Breast Cancer","Hormone Receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":{"count":60,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tamoxifen","otherNames":["Nolvadex","Soltamox"],"type":"DRUG"},{"name":"Anastrozole","otherNames":["Arimidex"],"type":"DRUG"},{"name":"Degarelix","otherNames":[],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["Verzenio"],"type":"DRUG"}],"last_update":"2026-08-24","lead_sponsor":"Jose Pablo Leone","official_title":"ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Change in Ki-67","timeFrame":"At the end of the 3-week window period."},{"measure":"RCB index","timeFrame":"At time of surgery."}],"references":[],"start_date":{"date":"2023-10-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ETHAN - ET for Male BC","url":"https://clinicaltrials.gov/study/NCT05501704"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05501704"}